Viewpoint: do antipsychotics protect against early death? A critical view

Area of Science:

• Psychiatry
• Pharmacology
• Public Health

Background:

• Prescription database studies suggest antipsychotics reduce mortality in schizophrenia patients.
• Conversely, studies on non-psychiatric populations indicate antipsychotics increase mortality risk due to adverse health effects.
• A significant mortality gap persists between individuals with serious mental illness and the general population.

Purpose of the Study:

• To critically review evidence on antipsychotic medication's impact on mortality in psychiatric patients.
• To address methodological and reporting issues in existing database studies.
• To investigate the contribution of antipsychotics to the mortality gap in serious mental illness.

Main Methods:

• Critical review of existing literature and prescription database studies.
• Analysis of methodological limitations in studies assessing medication usage.
• Examination of the 'drug-centered paradigm of care' in psychiatric treatment.

Main Results:

• Evidence suggests database studies on antipsychotics are plagued with methodological and reporting issues.
• Antipsychotics may contribute to the increased mortality observed in seriously mentally ill populations.
• The 'drug-centered paradigm' confounds comparisons of mortality risks between patients on and off antipsychotics.

Conclusions:

• The purported mortality-reducing effect of antipsychotics in schizophrenia patients requires re-evaluation.
• Antipsychotic medications may exacerbate, rather than alleviate, the mortality gap in serious mental illness.
• Future research must address study design flaws and the impact of care paradigms on mortality outcomes.